OncoSec Medical Incorporated · OTC:ONCSQ
OncoSec Medical — Investor Presentation (June 2015)
32 slides from OncoSec Medical's investor presentation, June 2015
Slide 1: Developing Intratumoral Immunotherapies to Target and Eliminate Cancer
Developing Intratumoral Immunotherapies to Target and Eliminate Cancer www.ON COS E C.co m
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT Our commentary and responses to your questions may contain forward looking statements, as described in the Private Securities Litigation Reform Act of 1995. These include comments concerning clinical trials and product development programs, evaluation of potential opportuni
Slide 3: Advancing a Leading Portfolio of Gene Therapies for Cancer
ADVANCING A LEADING P ORT FOL IO OF G ENE THE RAPIES FOR CA N C E R Developing therapeutic targets focused on overcoming tumor immune subversion Three clinical phase programs focused on addressing the significant unmet need of T-Cell poor tumors; enhancing the conversion of anti-PD-1 non-responders
Slide 4: Performance Update: Recent Events and Milestones
PE RFORMANCE UPDATE RECENT EVENTS AND MILESTONES Reported Phase I Long-term Survival Data in Melanoma Reported Positive Single-agent Phase II Final Data in Melanoma Completed Enrollment for Phase II Merkel Cell Carcinoma Study Announced a combination trial with Merck’s KEYTRUDA® First patient enroll
Slide 5: 'Adaptive Resistance' Phenotype Predicts Response to Anti-PD-1 in Melanoma
‘ADAP T I VE R E S I STA NCE’ PHENOTYPE PREDIC TS R E SP ON S E TO A NTI-PD-1 IN MELANOMA Adapted from Tumeh-PC, Nature. 2014 Nov 26; 515(7528): PD-1 blockade induces responses by in- hibiting adaptive immune resistance pIL-12-induced TIL generation provides rationale for combination with PD-1/PD-L1
Slide 6: T Cell-Poor Tumors: The Unmet Medical Need
T CELL-POOR TUMORS: THE UNMET MEDICAL NEED Tumor Type Anti-PD-1/PD-L1 mAb Non-Response Melanoma ~ 60 - 80% Triple Negative Breast (TNBC) ~ 70% - 82% 1 Renal Cell Carcinoma (RCC) ~ 71% Lung Carcinoma (NSCLC) ~ 79 - 83% Head & Neck (H&N) ~ 80% 2 Bladder ~ 84% 3 Gastric ~ 69% 2 Anti-PD-1 non-responders
Slide 7: Platform Technology
PLATFORM TECHNOLOGY Immune Block Stimulatory Inhibitory Molecules Molecules Overcoming Tumor Immune Tolerance With Intratumoral Immunotherapy Increase Decrease T-Lymphocyte Treg Infiltration Infiltration and/or Function Normalize Cell Adhesion & Trafficking 7
Slide 8: ImmunoPulse IL-12 Local Treatment, Global Results
IMMUNOPULSE™ IL-12 LOCAL TREATMENT GLOBAL RESULTS 1 2 3 4 Cancer Cells DNA IL-12 Injected Electroporation DNA IL-12 Enters 5 6 7 8 IL-12 Protein Expression Initiation of Local Targeted Anti-Tumor Immune Systemic Anti-Tumor Pro-Inflammatory Process Response & Lymphocyte Education Immune Response 8
Slide 9: Advantages of EP as a Gene Delivery Platform
A DVA NTAG E S O F E P AS A GENE DEL IVE RY PLATFOR M BENEFITS OF ELECTROPORATION VS. VIRAL VECTORS Intratumoral Electroporation Intratumoral Viral Vectors No neutralizing anti-drug immune response; allows Patients develop antibodies to the viral vector; for retreatment retreatment may not be effect
Slide 10: Phase II Clinical Data
PHASE II CL INICAL DATA IM M U N O P U L S E ™ I L-12 I N M E TASTATIC MELANOMA 10
Slide 11: Intratumoral Electroporation of IL-12 Is an Active Monotherapy
I NTRATUMORAL E LE C T ROPOR AT I ON OF I L-1 2 IS AN ACTIVE MONOT H E R APY ( N=29) 31+69+O 14+86+O 50+50+O 48+52+O 31% Best Overall Response Rate* 14% Complete Response Rate* 50% Patients With At Least One Non-Treated Lesion Regress 48% Disease Control Rate* * By Modified “Skin” RECIST Criteria 11
Slide 12: Complete Response to IL-12 EP
COMPLETE RESPONSE TO IL-12 EP Case #1 (001-003) Pre-Treatment Treated Scalp Lesions - Day 180 Pre-Treatment Untreated Parotid Lesion - Day 180 12
Slide 13: Safety Results
SAFETY RESULTS Treatment-Related Adverse Event* Grade 1 / 2 Grade 3 PAIN SCORE SUMMA RY 0 1 2 3 4 5 6 7 8 9 10 Pain 26 (87%) 1 (3%) Inflammation 5 (17%) No Pain Moderate Worst Pain Possible Pain Skin Discoloration 4 (13%) MEDIAN PAIN SCORE Fatigue Immediately After 2.00 Ecchymosis 0 5 Minutes After
Slide 14: Phase II Head & Neck Study
PHASE II HEAD & NECK STUDY IMMUNOPULSE™ IL-12 IN SQUAMOUS CELL CARCINOMA OF THE HEAD & NECK 14
Slide 15: Phase II Head & Neck Study
PHASE II HEAD & NECK STUDY IMMUNOPULSE™ IL-12 IN SQUAMOUS CELL CARCINOMA OF THE HEAD & NECK Rationale: biological mechanisms at play in metastatic melanoma also have a role in SCCHN Non-response to Anti-PD1 ~ 80% Patient Population: treatment-refractory metastatic and unresectable SCCHN N=~30 15
Slide 16: Pilot Study: Breast Cancer
PILOT STUDY: BREAST CANCE R 16
Slide 17: Pilot Study: Breast Cancer
PILOT STUDY: BREAST CANCE R Patient Population: Triple Negative Breast Cancer Estrogen-receptor negative Progesterone-receptor negative HER-2 Negative More aggressive, fewer treatment options, more likely to recur Phase I Studies KEYTRUDA® = 18.5% response rate (n=27) PD-L1 (MPDL3280A) = 33% respons
Slide 18: Clinical Pipeline
CL INICAL PIPEL INE Phase I Phase II Phase III Metastatic Melanoma Melanoma Combination study – IL12 + Anti-PD1 (KEYTRUDA®) Head & Neck Cancer Triple Negative Breast Cancer Orange = Monotherapy with IL-12 | Green = Combination Therapy 18
Slide 19: Preclinical Activities
PRECL INICAL ACTIVITIES Discovery Preclinical Pre-IND Heat Biologics (ImPACT Platform) Plexxikon (CSF-1R Inhibitor) Co-Stimulatory Molecules Pro-Inflammatory Cytokines Cell Trafficking Molecules 19
Slide 20: Key Points
KEY POINTS 1 2 3 A platform technology for pIL-12 electroporation delivering DNA-encoded Expanding the reach may promote conversion of immunomodulatory of immuno-oncology anti-PD-1 non-responders molecules to overcome to responders tumor immune tolerance 20
Slide 21: Upcoming Milestones
UPCOMING MILESTONES First Patient Enrolled & Interim Data readouts Melanoma Combination Study Head & Neck Study Triple Negative Breast Cancer Final Phase II Merkel Cell Carcinoma data Completion of Enrollment into Single-agent Phase II Melanoma Extention Study Pre-clinical data readouts IL-12 & GP96
Slide 22: Who We Are
WHO WE ARE Scientific Advisory Melanoma Advisory Senior Management Board of Directors Board Board Adil Daud, M.D. Punit Dhillon (Inovio, Lumira) Avtar Dhillon, M.D. (Inovio, Lumira) Soldano Ferrone, M.D., Ph.D. (University of California, San Francisco) Chief Executive Officer Chairman (Massachusetts
Slide 23: Who We Work With
WHO WE WORK WITH € MERCK © [> Heat Biologics PerkinE!imer Plexxikon @ Penn Stanford UCoF U C LA University University of California San Francisco MASSACHUSETTS dhatetana, SEATTLE c S tL aig -ENERAL HOSPITAL == fiona! ANCER CARE — Tatas ehter: ukejs ALLIANCE UNIVERSITY HEALTH NETWORK
Slide 24: Financial Background
FINANCIAL BACKGROUND AS O F JU NE 1 6, 201 5 NASDAQ ONCS Shares Outstanding 14,819,223 Market Cap $100 M Cash, Cash Equivalents and Short-Term Investments $36.2 M (as of June 6, 2015) Cash Runway Q2 2016 Debt $0 Analyst Coverage Reni Benjamin | H.C. Wainwright Analyst Coverage Jason Kolbert | Maxim
Slide 25: Thank You
THANK YOU SCAN THE CODE to download our complete Investor Overview www.OncoSec.com/ONCS-Investor-Package Telephone | 855.662.6732 OncoSec Headquaters Email | Investors@OncoSec.com 9810 Summers Ridge Road | Suite 110 Website | www.OncoSec.com San Diego, California | 92121
Slide 26: Appendix
APPENDIX 26
Slide 27: Anti-Tumor Efficacy Demonstrated in Phase I
ANTI-TUMOR EFFICACY DEMONSTRATED IN PHASE I 76+24+O 42+58+O 13+87+O 76% of Lesions Showed >20% Necrosis 42% Disease Control Rate* 13% of Patients Showed Complete Remission 49.1 10.9 23.9 MONTHS MONTHS MONTHS Median Overall Survival for Median Overall Survival Overall Survival in Patients with All Pa
Slide 28: Complete Response and Distant Lesion Regression Observed After 1 Cycle
COMPLETE RESPONSE AND DISTANT LESION REGRESSI ON OBSE RVED AFTE R 1 CYCLE OF LOCAL TREATMENT Numbered lesions on the chest were treated No lesions on the back were injected or electroporated 28
Slide 29: Intratumoral pIL-12 EP Can Lead to Durable Clinical Responses
INTRATUMORAL pIL-12 EP CAN LEAD TO DURABLE CL INICAL RESPONSES AND DISEASE STABIL IZATION 100% 80% Percent Change Tumor Burden From Baseline 60% 40% 20% CR 0 • • • • • • • • • • • • 2 • • • • • • • • • 4 • • • • • • • • • 6 • • • • • • • • • 8 • • • • • • • • 10 • • • • • • • • • 12 PR -20% SD -40%
Slide 30: pIL-12 EP Monotherapy Demonstrates Anti-Tumor Activity in Advanced Melanoma in Phase II
pIL-12 E P MONOT H E R A PY DE MON STRATE S A NTI-TUMOR AC TI VI T Y I N A DVA N CE D ME L A NOMA IN PHAS E II CR PR SD PD N=29 100+77+39+35+29+23+13+10+0+0+0+0 100% 80% 60% 40% 20% 0% -20% -40% -60% * * * * * * 100+100+100+100+60+59+5350+ +50+4722+ +20+19+1515+ 11+ +10 * * * -80% -100% * Patients w
Slide 31: Rationale for Intratumoral IL-12 as a Personalized Anti-Tumor Immunotherapy
RATIONALE FOR INTRATUMORAL IL-12 AS A PE RSONAL IZED ANTI-TUMOR IMMUNOTHE RAPY NK CTL TH0 IL-12 INF- T H1 M2 M1 31
Slide 32: References
REFE RENCES Tumeh-PC, Nature. 2014 Nov 26; 515(7528): PD-1 blockade induces responses by inhibiting adaptive immune resistance Daud et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. Journal of Clinical Oncology. 2008;26(36):5896–5903. Pardoll D. The